NuGen Medical Devices Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Lin Liang
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 18 King Street East Toronto ON Canada M5C 1C4
- IPO Date
- Feb 25, 2022
- Website
- nugenmd.com
- Similar Companies
- Business
- NuGen Medical Devices Inc. (TSXV: NGMD; OTCQB: NGMDF) develops and commercializes needle-free drug delivery technologies, including jet injector systems for subcutaneous medication administration; its primary product, InsuJet, delivers liquid drugs via high-pressure jet streams for applications in diabetes management, vaccines, growth and fertility hormones, semaglutide therapies, DNA vaccines, and pediatric vaccinations; additional offerings encompass veterinary solutions under PetJet for domesticated animals and home healthcare devices for self-administration in chronic disease treatment and hormone therapy. Headquartered in Toronto, Ontario, Canada, and founded in 2022 through the continuation of earlier operations, the company manufactures devices at its ISO 13485-certified facility in the Netherlands and markets products across more than 40 countries in Europe, Asia, North America, the Middle East, Latin America, and Africa, targeting healthcare practitioners, pharmacies, patients, and veterinary professionals with a focus on reducing needle-stick risks, improving drug uptake efficacy, and minimizing pain. Recent developments include the September 2025 announcement of a new needle-free injection system with internal cartridge technology; NHS Drug Tariff approval in the UK for the EziAutoJector product line in September 2025; strategic partnership with EziAutoJector Limited in October 2024 for UK distribution of 5,000 InsuJet devices; Canada-wide launch and expanded distribution of InsuJet starter packs through pharmacy partnerships with Sol-Millennium in 2024-2025; appointment of Liang Lin as Chief Executive Officer in January 2025; closing of a $10 million secured convertible debenture private placement in September 2024; repeat orders and distribution expansions into Mexico, Yemen, Romania, Argentina, Chile, Costa Rica, Peru, and Brazil within the last two years; and release of 2024 annual financial results alongside Q3 2025 earnings in April and December 2025, respectively, reflecting commercial momentum in pharmacy channels and global sales growth.
NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance
NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology
NuGen Medical Devices Inc. Provides Update on Health Canada License
NuGen Medical Devices Inc. Announces CFO Transition
NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress
NuGen Medical Devices Announces NHS Drug Tariff Approval for EziAutoJector(R) Product Line in the UK
Nugen Raises Pre-Seed to Pioneer Reliable AI for Businesses
NuGen Medical Devices Announces New Needle-Free Injection System Featuring Internal Cartridge Technology
InsuJet Distribution Expands Across France
NuGen Announces Release of 2024 Annual Financial Results
NuGen Announces the Appointment of Liang Lin as Chief Executive Officer
NuGen Announces Canada-Wide Launch of InsuJet
NuGen Announces Results of Special Meeting and Appointment of New Directors
NuGen Announces Strategic Partnership with EziAutoJector Limited
NuGen Announces Closing of Private Placement of $10 million Secured Convertible Debentures
NuGen Announces Release of Financial Results for Q2 2024 & Update on Proposed Private Placement
NuGen Announces Voting Results of Annual and Special Meeting
NuGen Announces Revised Terms of Proposed Private Placement of up to $10 Million Secured Convertible Debentures
NuGen Receives Order for Repeat Demand in Mexico
NuGen Announces Proposed Private Placement of up to $10 million Secured Convertible Debentures